Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new antibiotic is turning heads in UTI treatment. Gepotidacin, FDA-approved in March 2025, helped 54% of women with uncomplicated UTIs feel better within just 24 hours, according to a new clinical trial. By day 10, 90% had full symptom resolution — with no serious side effects reported.
A new antibiotic is making waves in UTI treatment. Gepotidacin, approved by the FDA in March 2025, delivered rapid symptom relief for women with uncomplicated urinary tract infections (uUTIs) in a new clinical trial published in JAMA Network Open. The drug works through a novel mechanism that inhibits bacterial replication — a welcome addition as antibiotic resistance continues to complicate standard UTI treatment.
The single-arm trial enrolled 97 female patients aged 12 and older, who took oral gepotidacin twice daily for five days. Researchers tracked symptom improvement at 24, 48, 72, and 96 hours, finding that relief came quickly and kept climbing over time. No serious adverse events were observed throughout the study.
By the Numbers:
Why it matters: With rising antibiotic resistance making UTI treatment increasingly tricky, gepotidacin offers clinicians a new, effective oral option — and gives patients and providers a clearer picture of what to expect during recovery.
